Moderna Inc. reported a surprise third-quarter profit for 2024, driven by higher-than-expected sales of its COVID-19 vaccine and cost-cutting measures. The company's revenue for the quarter reached $1.86 billion, surpassing the estimated $1.25 billion. Moderna's COVID-19 vaccine revenue alone amounted to $1.8 billion, exceeding the expected $1.2 billion. The company also reported a net income of $13 million, a significant turnaround from a net loss of $3.6 billion in the same quarter last year. Additionally, Moderna reiterated its forecast for 2024 product sales to be between $3.0 billion and $3.5 billion. The GAAP EPS for the quarter was $0.03. The company also reported RSV vaccine revenue of $10 million and cash and cash equivalents of $1.64 billion.